Genotoxicity testing of pidotimod in vitro and in vivo.
The mutagenic potential of pidotimod ((R)-3-[(S)-(5-oxo-2- pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was assessed in a series of five assays designed to measure gene mutation, chromosomal damage and primary DNA damage. All tests were carried out in accordance with appropriate EEC and OECD Guidelines. No indications of mutagenic potential were observed in any of the assays.
Adams
K
K
Department of Mutagenesis and Cell Biology, Huntingdon Research Centre Ltd., England.
Allen
J A
JA
Brooker
P C
PC
Henderson
L
L
Jones
E
E
Proudlock
R J
RJ
Mailland
F
F
Coppi
G
G
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D001854:Bone Marrow Cells; D016466:CHO Cells; D002478:Cells, Cultured; D002869:Chromosome Aberrations; D006224:Cricetinae; D004260:DNA Repair / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D015162:Micronucleus Tests; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D051381:Rats; D012486:Salmonella typhimurium / Q000187:drug effects / Q000235:genetics; D013844:Thiazoles / Q000633:toxicity*; D053778:Thiazolidines
D009153:Mutagens; D013844:Thiazoles; D053778:Thiazolidines; C064893:pidotimod; D011761:Pyrrolidonecarboxylic Acid